151 related articles for article (PubMed ID: 15996412)
1. Microvascular embolization following polidocanol microfoam sclerosant administration.
Eckmann DM; Kobayashi S; Li M
Dermatol Surg; 2005 Jun; 31(6):636-43. PubMed ID: 15996412
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of cerebrovascular gas emboli during polidocanol endovenous ultra-low nitrogen microfoam ablation and correlation with magnetic resonance imaging in patients with right-to-left shunt.
Regan JD; Gibson KD; Rush JE; Shortell CK; Hirsch SA; Wright DD
J Vasc Surg; 2011 Jan; 53(1):131-7. PubMed ID: 20864303
[TBL] [Abstract][Full Text] [Related]
3. Polidocanol for endovenous microfoam sclerosant therapy.
Eckmann DM
Expert Opin Investig Drugs; 2009 Dec; 18(12):1919-27. PubMed ID: 19912070
[TBL] [Abstract][Full Text] [Related]
4. Benefits of polidocanol endovenous microfoam (Varithena®) compared with physician-compounded foams.
Carugo D; Ankrett DN; Zhao X; Zhang X; Hill M; O'Byrne V; Hoad J; Arif M; Wright DD; Lewis AL
Phlebology; 2016 May; 31(4):283-95. PubMed ID: 26036246
[TBL] [Abstract][Full Text] [Related]
5. Novel developments in foam sclerotherapy: Focus on Varithena® (polidocanol endovenous microfoam) in the management of varicose veins.
Star P; Connor DE; Parsi K
Phlebology; 2018 Apr; 33(3):150-162. PubMed ID: 28166694
[TBL] [Abstract][Full Text] [Related]
6. Microfoam sclerotherapy.
Redondo P; Cabrera J
Semin Cutan Med Surg; 2005 Dec; 24(4):175-83. PubMed ID: 16387261
[TBL] [Abstract][Full Text] [Related]
7. Percutaneous ultrasound-guided sclerotherapy with polidocanol microfoam for lymphatic malformations.
Yamaki T; Sasaki Y; Hasegawa Y; Osada A; Konoeda H; Hamahata A; Nozaki M; Sakurai H
J Vasc Surg Venous Lymphat Disord; 2017 Sep; 5(5):707-714. PubMed ID: 28818226
[TBL] [Abstract][Full Text] [Related]
8. The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence.
Todd KL; Wright DI;
Phlebology; 2014 Oct; 29(9):608-18. PubMed ID: 23864535
[TBL] [Abstract][Full Text] [Related]
9. Treatment of venous malformations with sclerosant in microfoam form.
Cabrera J; Cabrera J; Garcia-Olmedo MA; Redondo P
Arch Dermatol; 2003 Nov; 139(11):1409-16. PubMed ID: 14623700
[TBL] [Abstract][Full Text] [Related]
10. Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2).
Todd KL; Wright DI;
J Vasc Surg Venous Lymphat Disord; 2015 Jul; 3(3):258-264.e1. PubMed ID: 26992303
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Truncal Incompetence and Varicose Veins with a Single Administration of a New Polidocanol Endovenous Microfoam Preparation Improves Symptoms and Appearance.
King JT; O'Byrne M; Vasquez M; Wright D;
Eur J Vasc Endovasc Surg; 2015 Dec; 50(6):784-93. PubMed ID: 26384639
[TBL] [Abstract][Full Text] [Related]
12. Polidocanol concentration and time affect the properties of foam used for sclerotherapy.
VAN Deurzen B; Ceulen RP; Tellings SS; VAN DER Geld C; Nijsten T
Dermatol Surg; 2011 Oct; 37(10):1448-55. PubMed ID: 21790848
[TBL] [Abstract][Full Text] [Related]
13. Reversible cardiac arrest after polidocanol sclerotherapy of peripheral venous malformation.
Marrocco-Trischitta MM; Guerrini P; Abeni D; Stillo F
Dermatol Surg; 2002 Feb; 28(2):153-5. PubMed ID: 11860427
[TBL] [Abstract][Full Text] [Related]
14. Microvascular gas embolization clearance following perfluorocarbon administration.
Eckmann DM; Lomivorotov VN
J Appl Physiol (1985); 2003 Mar; 94(3):860-8. PubMed ID: 12571123
[TBL] [Abstract][Full Text] [Related]
15. Indications for the sclerosing agent polidocanol (aetoxisclerol dexo, aethoxisklerol kreussler).
Guex JJ
J Dermatol Surg Oncol; 1993 Oct; 19(10):959-61. PubMed ID: 8408916
[TBL] [Abstract][Full Text] [Related]
16. A new automated system for the preparation of sclerosant foam: A study of the physical characteristics produced and the device settings required.
Roche E; Pons R; Roche O; Puig A
Phlebology; 2020 Oct; 35(9):724-733. PubMed ID: 32635818
[TBL] [Abstract][Full Text] [Related]
17. Sclerotherapy: a study comparing polidocanol in foam and liquid form.
Uncu H
Phlebology; 2010 Feb; 25(1):44-9. PubMed ID: 20118346
[TBL] [Abstract][Full Text] [Related]
18. Venous gas embolism during foam sclerotherapy of saphenous veins despite recommended treatment modifications.
Parsi K
Phlebology; 2011 Jun; 26(4):140-7. PubMed ID: 21087951
[TBL] [Abstract][Full Text] [Related]
19. Foam sclerotherapy using polidocanol (aethoxysklerol) for preoperative portal vein embolization in 16 patients.
Chung SH; Lee MS; Kim KS; Kim SI; Won JY; Lee DY; Lee KH
Cardiovasc Intervent Radiol; 2011 Dec; 34(6):1236-43. PubMed ID: 21290126
[TBL] [Abstract][Full Text] [Related]
20. Effects of 1064-nm Nd:YAG long-pulse laser on polidocanol microfoam injected for varicose vein treatment: a controlled observational study of 404 legs, after 5-year-long treatment.
Moreno-Moraga J; Pascu ML; Alcolea JM; Smarandache A; Royo J; David F; Trelles MA
Lasers Med Sci; 2019 Sep; 34(7):1325-1332. PubMed ID: 30707327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
